Novo Nordisk filed lawsuits against multiple med-spas that are distributing compounded versions of Semaglutide. Semaglutide is the main ingredient in Ozempic, Wegovy, and Rybelsus—popular weight-loss medications. Their popularity resulted in nationwide shortages and the FDA listing Ozempic and Wegovy on the shortage list. Under certain conditions, compounding facilities can manufacture drugs identical, or near identical, …